PT UBC Medical Indonesia Tbk (IDX:LABS)

Market Cap	620.15B +11.3%
Revenue (ttm)	207.82B +22.4%
Net Income	10.69B +29.7%
EPS	2.71 +29.7%
Shares Out	3.95B
PE Ratio	58.75
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	574,900
Open	158.00
Previous Close	159.00
Day's Range	157.00 - 161.00
52-Week Range	129.00 - 260.00
Beta	-0.17
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 30, 2026

About IDX:LABS

PT UBC Medical Indonesia Tbk distributes medical devices in Indonesia. It operates in two segments, Medical Disposables and Consumables; and Diagnostics and Equipment. The company offers NeoMoDX molecular system; Revvity SARS-COV-2 RT PCR and Geneproof SARS-COV-2 PCR KIT; Airdoc Retina AI, a screening technology that uses Artificial Intelligence (AI) to detect chronic diseases such as diabetic retinopathy and hypertension; Hisky; and All-in-one GP workstation. It also provides TB management products, such as Quantiferon TB Hold Plus, Genoschola...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2014
• Employees: 54
• Stock Exchange: Indonesia Stock Exchange
• Ticker Symbol: LABS

Financial Performance

In 2025, IDX:LABS's revenue was 199.30 billion, an increase of 34.99% compared to the previous year's 147.64 billion. Earnings were 13.51 billion, an increase of 357.50%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error